Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients.
Ebbo M, Grados A, Samson M, Groh M, Loundou A, Rigolet A, Terrier B, Guillaud C, Carra-Dallière C, Renou F, Pozdzik A, Labauge P, Palat S, Berthelot JM, Pennaforte JL, Wynckel A, Lebas C, Le Gouellec N, Quémeneur T, Dahan K, Carbonnel F, Leroux G, Perlat A, Mathian A, Cacoub P, Hachulla E, Costedoat-Chalumeau N, Harlé JR, Schleinitz N.
Ebbo M, et al. Among authors: groh m.
PLoS One. 2017 Sep 15;12(9):e0183844. doi: 10.1371/journal.pone.0183844. eCollection 2017.
PLoS One. 2017.
PMID: 28915275
Free PMC article.
Clinical Trial.